Thorsson et al. (2018) also identified six immune subgroups spanning multiple tumor groups, including EC, based on differences in macrophages or lymphocytes. Patients in the C3 (inflammatory) subgroup had the best prognoses. In contrast, those in the C2 (INF-gamma dominant) and C1 (wound healing) subgroups had less favorable outcomes, and those in the C4 (lymphocyte depleted) and C6 (TGF-b dominant) subgroups had the worst outcomes (Thorsson et al., 2018; Mullen and Mutch, 2019). The gene discussed is TGFB1; the disease is neoplasm.